Show simple item record

dc.contributor.authorHelming, Katherine C.en_US
dc.contributor.authorWang, Xiaofengen_US
dc.contributor.authorWilson, Boris G.en_US
dc.contributor.authorVazquez, Franciscaen_US
dc.contributor.authorHaswell, Jeffrey R.en_US
dc.contributor.authorManchester, Haley E.en_US
dc.contributor.authorKim, Younghaen_US
dc.contributor.authorKryukov, Gregory V.en_US
dc.contributor.authorGhandi, Mahmouden_US
dc.contributor.authorAguirre, Andrew J.en_US
dc.contributor.authorJagani, Zainaben_US
dc.contributor.authorWang, Zhongen_US
dc.contributor.authorGarraway, Levi A.en_US
dc.contributor.authorHahn, William C.en_US
dc.contributor.authorRoberts, Charles W. M.en_US
dc.date.accessioned2014-10-01T14:27:32Z
dc.date.issued2014en_US
dc.identifier.citationHelming, K. C., X. Wang, B. G. Wilson, F. Vazquez, J. R. Haswell, H. E. Manchester, Y. Kim, et al. 2014. “ARID1B is a specific vulnerability in ARID1A-mutant cancers.” Nature medicine 20 (3): 251-254. doi:10.1038/nm.3480. http://dx.doi.org/10.1038/nm.3480.en
dc.identifier.issn1078-8956en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:12987227
dc.description.abstractSummary Recent studies have revealed that ARID1A is frequently mutated across a wide variety of human cancers and also has bona fide tumor suppressor properties. Consequently, identification of vulnerabilities conferred by ARID1A mutation would have major relevance for human cancer. Here, using a broad screening approach, we identify ARID1B, a related but mutually exclusive homolog of ARID1A in the SWI/SNF chromatin remodeling complex, as the number one gene preferentially required for the survival of ARID1A-mutant cancer cell lines. We show that loss of ARID1B in ARID1A-deficient backgrounds destabilizes SWI/SNF and impairs proliferation. Intriguingly, we also find that ARID1A and ARID1B are frequently co-mutated in cancer, but that ARID1A-deficient cancers retain at least one ARID1B allele. These results suggest that loss of ARID1A and ARID1B alleles cooperatively promotes cancer formation but also results in a unique functional dependence. The results further identify ARID1B as a potential therapeutic target for ARID1A-mutant cancers.en
dc.language.isoen_USen
dc.relation.isversionofdoi:10.1038/nm.3480en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954704/pdf/en
dash.licenseLAAen_US
dc.titleARID1B is a specific vulnerability in ARID1A-mutant cancersen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalNature medicineen
dash.depositing.authorWang, Xiaofengen_US
dc.date.available2014-10-01T14:27:32Z
dc.identifier.doi10.1038/nm.3480*
dash.authorsorderedfalse
dash.contributor.affiliatedWilson, Boris G.
dash.contributor.affiliatedAguirre, Andrew
dash.contributor.affiliatedManchester, Haley
dash.contributor.affiliatedHaswell, Jeffrey
dash.contributor.affiliatedWang, Xiaofeng
dash.contributor.affiliatedKryukov, Gregory V.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record